Lupus & antiphospholipid syndrome
Upadacitinib enhances platelet procoagulant responses in a subset of healthy individuals and patients with SLE: a pilot study
Authors' conclusion
Upadacitinib was associated with enhanced platelet activation and procoagulant responses in vitro in a subset of individuals with SLE and healthy controls.
Study context
- Population
- Patients with SLE and healthy controls; whole blood preincubated with upadacitinib in vitro
- Participants
- 10 vs 10
- Comparison
- Upadacitinib (0, 60 and 300 ng/mL) preincubation of whole blood from patients with SLE and healthy controls
- SLEn = 10
- Healthy controlsn = 10reference
- Outcome
- Platelet procoagulant membrane dynamics (PMD) markers on JAK inhibition and associated cytokine signatures
Methodological detailspilot study, in vitro
- Pilot study
- In vitro
Main finding
As reported in the abstract
Platelet responses were heterogeneous; ≈30% of both groups had increased platelet activation and procoagulant responses (JAKi-activated), the remainder unaffected
≈30%
Further findings
Recombinant IL-4 and TNF-β in vitro
- Directly activated platelets or primed platelet responses to procoagulant agonists
Original publication
Upadacitinib enhances platelet procoagulant responses in a subset of healthy individuals and patients with SLE: a pilot study. Lupus Sci Med. Published 7 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →